J&J sales top forecast, helped by hepatitis drug
Nobel Biocare’s Q2 profits double as it fields buyout interest
ConvaTec said to explore 2015 sale
Medtronic’s Q1 earnings beat The Street on modest sales bump
Diabetes: DexCom’s revenues jump 64% in Q2
EnteroMedics’ losses widen as it chases FDA approval
Minnesota-based EnteroMedics (NSDQ:ETRM) gained modestly this week after announcing its latest financial report, even though the company missed the mark by a penny.
Strong Q4, $750M buyback give CareFusion a boost
CareFusion (NYSE:CFN) posted a stellar 4th-quarter, posting double-digit growth in revenues and earnings and beating Wall Street’s estimates.
Masimo sinks as Q2 misses the mark
Baxano: Strong Q2, new patents can’t appease Wall Street
Baxano Surgical (NSDQ:BAXS) just can’t seem to do right by Wall Street.
Thoratec’s new study, $30M buyback can’t stave off Wall Street exodus after dismal Q2
Struggling Alere plans to shed some skin after rough Q2
- 1
- 2
- 3
- …
- 18
- Next Page »
